Safety and efficacy of lenalidomide for patients with relapsed or refractory adult T cell leukemia/lymphoma post allogeneic hematopoietic stem cell transplantation, multi-institutional prospective observational trial
Not Applicable
- Conditions
- Adult T-cell leukemia-lymphoma
- Registration Number
- JPRN-UMIN000029635
- Lead Sponsor
- Kagoshima University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
1. History of lenalidomide administration after allogeneic hematopoietic stem cell transplantation 2. Plant to move within one year after registry 3. Inappropriate condition by physician's decision 4. Pregnancy or under breast-feeding or plat to pregnant during registry
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method One-year overall survival after hematopoietic stem cell transplantation
- Secondary Outcome Measures
Name Time Method